Key result
ePLAR (0.37 vs 0.23 m/s) and epicardial adipose tissue (0.62 vs 0.53 cm) were significantly higher in OSAS patients than controls and increased stepwise with disease severity.
Why the study?
Obstructive sleep apnea syndrome is linked to pulmonary hypertension and cardiovascular risk, yet simple echocardiographic indices reflecting cardiopulmonary hemodynamics and cardiometabolic burden are limited.
Do echocardiographic markers ePLAR and EAT correlate with the presence and severity of obstructive sleep apnea syndrome?
Do echocardiographic markers ePLAR and EAT correlate with the presence and severity of obstructive sleep apnea syndrome?
Echocardiographic measurement of ePLAR and epicardial adipose tissue thickness can serve as noninvasive markers to identify the presence and severity of obstructive sleep apnea.
Supports noninvasive OSAS assessment via echo ePLAR and EAT; extends PH-CV risk links but should not yet change practice.
Background Obstructive sleep apnea syndrome (OSAS) is linked to pulmonary hypertension and cardiovascular risk, yet simple echocardiographic indices related to cardiopulmonary hemodynamics and cardiometabolic burden are limited. We evaluated ePLAR and epicardial adipose tissue (EAT) thickness as complementary, noninvasive echocardiographic markers associated with OSAS presence and severity in newly diagnosed patients. Methods In this cross‐sectional study, 63 polysomnography‐confirmed OSAS patients and 63 controls with a similar distribution of age, sex, and major comorbidities underwent transthoracic echocardiography. OSAS severity was classified as mild, moderate, or severe. ePLAR (TRVmax/E/e′) and EAT were measured. Diagnostic performance was assessed by ROC analysis (apparent discrimination), and prediction models for severe OSAS were fitted using Firth penalized logistic regression with bootstrap optimism correction. Results OSAS patients had higher EAT (0.62 ± 0.11 vs. 0.53 ± 0.06 cm) and ePLAR (0.37 ± 0.09 vs. 0.23 ± 0.04 m/s) than controls (both p < 0.001). Within OSAS, both measures increased stepwise with severity ( p < 0.001). In internally validated models, adding ePLAR and/or EAT to age/sex/BMI improved discrimination for severe OSAS. Conclusions EPLAR and EAT were associated with OSAS presence and severity and showed good apparent discrimination for severe OSAS in this cohort; these findings are hypothesis‐generating and require external validation in clinically representative populations before any clinical implementation. Trial Registration This study was observational and cross‐sectional in design and was not registered in a clinical trial registry because it was not an interventional clinical trial.
No takes yet. Share an insight, caveat, or question.
Ceylan et al. (2026) studied this question. ePLAR (0.37 vs 0.23 m/s) and epicardial adipose tissue (0.62 vs 0.53 cm) were significantly higher in OSAS patients than controls and increased stepwise with disease severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: